TrialJournal for immunotherapy of cancer2023

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.

Mehmet Altan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.